top of page

Occam Places Aron Feingold as VP of Investor Relations & Corporate Communications at Geron

Geron is a public, clinical stage biotech company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, with disease modification potential for myeloid hematologic malignancies.

In early 2022, Occam placed Aron Feingold (former Sangamo and Pfizer), as VP of Investor Relations & Corporate Communications, a role crucial to Geron at this point in its evolution, as it approaches potential registration and commercialization.

bottom of page